Isoray, Inc. provided sales guidance for the first quarter ending September 30, 2022. In the short term, although the company don't have adequate supply now of Cesium-131, the company expects a decline in sales in the first fiscal quarter of 2023 ending September 30, 2022, versus the prior year. The company currently anticipates total revenue for this period to be between $1.6 million and $1.8 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.38 USD | +0.73% | -11.54% | +243.28% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+243.28% | 930M | |
+46.19% | 55.7B | |
-6.14% | 39.57B | |
+39.19% | 39.91B | |
-6.65% | 28.16B | |
+12.33% | 26.3B | |
-21.78% | 18.94B | |
-0.35% | 12.12B | |
+24.18% | 12.12B | |
+28.38% | 12.17B |
- Stock Market
- Equities
- CATX Stock
- News Perspective Therapeutics, Inc.
- Isoray, Inc. Provides Sales Guidance for the First Quarter Ending September 30, 2022